---
title: "VK2735 in Chronic weight management: References"
description: "Reference list for the formulary evidence report on VK2735 in Chronic weight management. 184 cited documents."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: References

<a id="references"></a>

## 5 References

1. [Alkhouri et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/Results-From-the-13-Week-VENTURE-Phase-2a-Study-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Obese-Patients.pdf)
2. [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690172/)
3. [Apovian et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25590212/)
4. [Ard et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Ard_OW2026_VANQUISH-2_poster-FINAL.pdf)
5. [Aronne et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10714284/)
6. [Aronne et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40353578/)
7. [Aronne et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13375559/)
8. [Atlas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10387935/)
9. [Bays et al. (2025)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/Impact-of-Subcutaneous-VK2735-on-Weight-Prediabetes-and-Cardiometabolic-Status-The-VENTURE-Study.pdf)
10. [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)
11. [Bays et al. (2026b)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Bays_OW2026_VENTURE_CM_Impact_poster-FINAL.pdf)
12. [Betensky et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13229537/)
13. [Bhaskaran et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6249991/)
14. [Busebee et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10843116/)
15. [Busetto et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38969880/)
16. [Cawley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10394178/)
17. [CBO (2024)](https://www.cbo.gov/publication/60441)
18. [CDC Adult BMI Categories (2024)](https://www.cdc.gov/bmi/adult-calculator/bmi-categories.html)
19. [CDC Adult Obesity Prevalence Maps (2026)](https://www.cdc.gov/obesity/data-and-statistics/adult-obesity-prevalence-maps.html)
20. [CDC Risk Factors for Obesity (2025)](https://www.cdc.gov/obesity/risk-factors/risk-factors.html)
21. [Celletti et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41324410/)
22. [Chao et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7437140/)
23. [Chetty et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12045892/)
24. [Chung et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Chung_EISPOR_2026_VENTURE_Predicted_CV_Risk_poster-FINAL.pdf)
25. [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237)
26. [ClinicalTrials.gov NCT06068946](https://clinicaltrials.gov/study/NCT06068946)
27. [ClinicalTrials.gov NCT06828055](https://clinicaltrials.gov/study/NCT06828055)
28. [ClinicalTrials.gov NCT07104383](https://clinicaltrials.gov/study/NCT07104383)
29. [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500)
30. [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)
31. [ClinicalTrials.gov NCT07868835](https://clinicaltrials.gov/study/NCT07868835)
32. [ClinicalTrials.gov NCT07868939](https://clinicaltrials.gov/study/NCT07868939)
33. [CMS BALANCE Model (2026)](https://www.cms.gov/priorities/innovation/innovation-models/balance)
34. [CMS Medicare GLP-1 Bridge (2026)](https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge)
35. [CMS Quality Payment Program measure 128 (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_128_MIPSCQM.pdf)
36. [Davies et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33667417/)
37. [Do et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11127113/)
38. [Eisenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9834364/)
39. [Eli Lilly Foundayo approval announcement (2026)](https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill)
40. [Eli Lilly Foundayo coverage and savings (2026)](https://foundayo.lilly.com/hcp/savings-coverage)
41. [Eli Lilly Foundayo prescribing information (2026)](https://uspl.lilly.com/foundayo/foundayo.html)
42. [Eli Lilly Zepbound coverage and savings (2026)](https://zepbound.lilly.com/hcp/coverage-savings)
43. [Eli Lilly Zepbound KwikPen announcement (2026)](https://investor.lilly.com/news-releases/news-release-details/zepbound-tirzepatide-most-prescribed-weight-management)
44. [Eli Lilly Zepbound prescribing information (2026)](https://uspl.lilly.com/zepbound/zepbound.html)
45. [Eli Lilly Zepbound pricing information (2026)](https://www.lillypricinginfo.com/zepbound)
46. [Emmerich et al. (2024)](https://www.cdc.gov/nchs/products/databriefs/db508.htm)
47. [FDA weight reduction draft guidance (2025)](https://www.fda.gov/media/71252/download)
48. [FDA weight reduction draft guidance notice (2025)](https://www.govinfo.gov/content/pkg/FR-2025-01-08/html/2025-00237.htm)
49. [Flølo et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12705258/)
50. [Fryar et al. (2026)](https://www.cdc.gov/nchs/data/hestat/hestat111.htm)
51. [Gadde et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21481449/)
52. [Garvey et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9556320/)
53. [Garvey et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37385275/)
54. [Garvey et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40544433/)
55. [GBD 2015 Obesity Collaborators (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5477817/)
56. [GBD 2021 Adult BMI Collaborators (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11920007/)
57. [GBD 2021 US Obesity Forecasting Collaborators (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11694015/)
58. [Gilbert et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40539956/)
59. [Gleason et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11293763/)
60. [Global BMI Mortality Collaboration (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4995441/)
61. [Greenway et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20673995/)
62. [Grunvald et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36273831/)
63. [Guh et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2667420/)
64. [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)
65. [Hennessy et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41637062/)
66. [Horn et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/42119587/)
67. [Horn et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13453602/)
68. [Hwang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11909610/)
69. [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)
70. [Ippolito and Levy (2024)](https://pubmed.ncbi.nlm.nih.gov/39146500/)
71. [ISRCTN ISRCTN47896018](https://www.isrctn.com/ISRCTN47896018)
72. [Jastreboff et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35658024/)
73. [Jastreboff et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39536238/)
74. [Jastreboff et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42814954/)
75. [Jensen et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5819889/)
76. [Johansson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42012820/)
77. [KFF (2025)](https://www.kff.org/health-costs/2025-employer-health-benefits-survey/)
78. [Kim et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10372962/)
79. [Kivimäki et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8938400/)
80. [Kolotkin and Andersen (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5600094/)
81. [Kolotkin et al. (2017a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5599949/)
82. [Kosiborod et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37622681/)
83. [Lauby-Secretan et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6754861/)
84. [Lian et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1002/oby.23938)
85. [Lincoff et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37952131/)
86. [Lingvay et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40961953/)
87. [Luppino et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20194822/)
88. [MacEwan et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10804324/)
89. [Malhotra et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11598664/)
90. [Marshall et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948759/)
91. [Mercer (2025)](https://www.mercer.com/en-us/about/newsroom/employers-and-workers-face-affordability-crunch-as-health-insurnace-cost-is-expected-to-exceed-18500-per-employee-in-2026/)
92. [Modesto et al. (2025a)](https://www.ahajournals.org/doi/10.1161/circ.152.suppl_3.4367152)
93. [Modesto et al. (2025b)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-1-Design-Phase-3-Trial-of-Subcutaneous-VK2735-in-Adults-with-Overweight-or-Obesity.pdf)
94. [Modesto et al. (2025c)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-2-Phase-3-Randomized-Double-blind-Placebo-controlled-Trial-of-weekly-subcutaneous-administration-of-VK2735-in-Obese-or-Overweight.pdf)
95. [Montero et al. (2024)](https://www.kff.org/health-costs/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs/)
96. [Nadolsky et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40956256/)
97. [NCD Risk Factor Collaboration (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7615769/)
98. [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)
99. [Nielsen et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10196588/)
100. [Novo Nordisk list price reduction announcement (2026)](https://www.novonordisk-us.com/media/press-releases/novo-nordisk-lowers-wegovy-ozempic-list-price.html)
101. [Novo Nordisk Wegovy pill approval announcement (2025)](https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-302648344.html)
102. [Novo Nordisk Wegovy prescribing information (2026)](https://www.novo-pi.com/wegovy.pdf)
103. [Novo Nordisk Wegovy pricing information (2026)](https://www.novopricing.com/wegovy.html)
104. [ODPHP Healthy People 2030 NWS-03](https://odphp.health.gov/healthypeople/objectives-and-data/browse-objectives/overweight-and-obesity/reduce-proportion-adults-obesity-nws-03)
105. [Okunogbe et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9494015/)
106. [Pennings et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11997402/)
107. [Peppard et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3639722/)
108. [Pi-Sunyer et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26132939/)
109. [Powell-Wiley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8493650/)
110. [Rodriguez et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11786232/)
111. [Ross et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7027970/)
112. [Rozjabek et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7306452/)
113. [Rubino et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7154011/)
114. [Rubino et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38698650/)
115. [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)
116. [Ryan et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11271387/)
117. [Sanyal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40305708/)
118. [Schwartz et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5546881/)
119. [Shinde et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11229424/)
120. [Syn et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33965067/)
121. [Tchang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12015656/)
122. [Thorpe and Joski (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11621981/)
123. [Torgerson et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/14693982/)
124. [US Preventive Services Task Force (2018)](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/obesity-in-adults-interventions)
125. [Vasan et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16204159/)
126. [Viking Therapeutics chief commercial officer appointment release (2026)](https://ir.vikingtherapeutics.com/2026-01-07-Viking-Therapeutics-Announces-Appointment-of-Neil-Aubuchon-as-Chief-Commercial-Officer)
127. [Viking Therapeutics CordenPharma agreement release (2025)](https://ir.vikingtherapeutics.com/2025-03-11-Viking-Therapeutics-Signs-Broad-Manufacturing-Agreement-With-CordenPharma-to-Support-Commercialization-of-VK2735)
128. [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)
129. [Viking Therapeutics ECO 2026 release (2026)](https://ir.vikingtherapeutics.com/2026-05-12-Viking-Therapeutics-Presents-Data-from-its-13-Week-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-at-European-Congress-on-Obesity-ECO-2026)
130. [Viking Therapeutics first quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/555372-q1-2026/)
131. [Viking Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526046876/vktx-20251231.htm)
132. [Viking Therapeutics Form 10-Q third quarter (2026)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526436432/vktx-20260930.htm)
133. [Viking Therapeutics fourth quarter 2024 results release (2025)](https://ir.vikingtherapeutics.com/2025-02-05-Viking-Therapeutics-Reports-Fourth-Quarter-and-Year-End-2024-Financial-Results-and-Provides-Corporate-Update)
134. [Viking Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/401860-q4-2025/)
135. [Viking Therapeutics fourth quarter 2025 results release (2026)](https://ir.vikingtherapeutics.com/2026-02-11-Viking-Therapeutics-Reports-Fourth-Quarter-and-Year-End-2025-Financial-Results-and-Provides-Corporate-Update)
136. [Viking Therapeutics J.P. Morgan conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/537697-44th-annual-j-p-morgan-healthcare-conference/)
137. [Viking Therapeutics Jefferies conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/678533-jefferies-global-healthcare-conference-2026/)
138. [Viking Therapeutics Jefferies London conference transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/412049-jefferies-london-healthcare-conference-2025/)
139. [Viking Therapeutics maintenance study enrollment release (2026)](https://ir.vikingtherapeutics.com/2026-01-08-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Maintenance-Dosing-Clinical-Trial-of-VK2735-in-Obesity)
140. [Viking Therapeutics maintenance study initiation release (2025)](https://ir.vikingtherapeutics.com/2025-10-21-Viking-Therapeutics-Announces-Initiation-of-VK2735-Maintenance-Dosing-Clinical-Trial-in-Patients-with-Obesity)
141. [Viking Therapeutics maintenance study presentation (2026)](https://ir.vikingtherapeutics.com/image/Maintenance+Study+Presentation.pdf)
142. [Viking Therapeutics maintenance study topline call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/758817-study-result/)
143. [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)
144. [Viking Therapeutics Morgan Stanley conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/744429-morgan-stanley-24th-annual-global-healthcare-conference/)
145. [Viking Therapeutics ObesityWeek 2021 preclinical release (2021)](https://ir.vikingtherapeutics.com/2021-11-01-Viking-Therapeutics-Presents-Preclinical-Data-on-Novel-Dual-GLP-1-GIP-Agonists-at-ObesityWeek-R-2021)
146. [Viking Therapeutics ObesityWeek 2023 release (2023)](https://ir.vikingtherapeutics.com/2023-10-17-Viking-Therapeutics-Presents-New-Data-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Oral-Presentation-at-ObesityWeek-2023)
147. [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)
148. [Viking Therapeutics ObesityWeek 2025 release (2025)](https://ir.vikingtherapeutics.com/2025-11-06-Viking-Therapeutics-Highlights-Clinical-Data-from-VK2735-Obesity-Program-in-Presentation-at-ObesityWeek-R-2025)
149. [Viking Therapeutics ObesityWeek 2026 release (2026)](https://ir.vikingtherapeutics.com/2026-11-15-Viking-Therapeutics-Highlights-Clinical-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2026)
150. [Viking Therapeutics oral maintenance study initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-06-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Maintenance-Dosing-Clinical-Trial-in-Patients-with-Obesity)
151. [Viking Therapeutics oral phase 1 initiation release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Initiation-of-Phase-1-Study-to-Evaluate-Oral-Formulation-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)
152. [Viking Therapeutics oral phase 1 results release (2024)](https://ir.vikingtherapeutics.com/2024-03-26-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Oral-Tablet-Formulation-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)
153. [Viking Therapeutics phase 1 initiation release (2022)](https://ir.vikingtherapeutics.com/2022-01-10-Viking-Therapeutics-Announces-Initiation-of-Phase-1-Clinical-Trial-of-VK2735,-Companys-Lead-Dual-GLP-1-GIP-Receptor-Agonist)
154. [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)
155. [Viking Therapeutics second quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/657331-q2-2026/)
156. [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)
157. [Viking Therapeutics third quarter 2024 results release (2024)](https://ir.vikingtherapeutics.com/2024-10-23-Viking-Therapeutics-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Corporate-Update)
158. [Viking Therapeutics third quarter 2025 earnings call transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/366279-q3-2025/)
159. [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)
160. [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)
161. [Viking Therapeutics VANQUISH initiation release (2025)](https://ir.vikingtherapeutics.com/2025-06-25-Viking-Therapeutics-Announces-Initiation-of-Phase-3-Obesity-Clinical-Program-with-GLP-1-GIP-Agonist-VK2735)
162. [Viking Therapeutics VANQUISH-1 enrollment release (2025)](https://ir.vikingtherapeutics.com/2025-11-19-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-3-VANQUISH-1-Trial-of-VK2735)
163. [Viking Therapeutics VANQUISH-2 enrollment release (2026)](https://ir.vikingtherapeutics.com/2026-03-26-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-3-VANQUISH-2-Trial-of-VK2735)
164. [Viking Therapeutics VENTURE enrollment release (2023)](https://ir.vikingtherapeutics.com/2023-10-23-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Patients-with-Obesity)
165. [Viking Therapeutics VENTURE initiation release (2023)](https://ir.vikingtherapeutics.com/2023-09-06-Viking-Therapeutics-Announces-Initiation-of-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Patients-with-Obesity)
166. [Viking Therapeutics VENTURE topline release (2024)](https://ir.vikingtherapeutics.com/2024-02-27-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Patients-with-Obesity)
167. [Viking Therapeutics VENTURE-Oral enrollment release (2025)](https://ir.vikingtherapeutics.com/2025-03-26-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)
168. [Viking Therapeutics VENTURE-Oral initiation release (2025)](https://ir.vikingtherapeutics.com/2025-01-08-Viking-Therapeutics-Announces-Initiation-of-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)
169. [Viking Therapeutics VENTURE-Oral topline call transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/377050-study-result/)
170. [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)
171. [Viking Therapeutics VK2735 pipeline page](https://vikingtherapeutics.com/pipeline/vk2735/)
172. [Ward et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31851800/)
173. [Ward et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7990296/)
174. [West et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12776922/)
175. [Wharton et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/40961952/)
176. [Wharton et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40960239/)
177. [Wharton et al. (2025c)](https://pubmed.ncbi.nlm.nih.gov/40934115/)
178. [WHO (2026)](https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight)
179. [Wilding et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33567185/)
180. [Wilding et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9542252/)
181. [Wyatt et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/VANQUISH-1-Phase-3-Trial-with-Enrollment-of-a-Diverse-Population-to-Test-Efficacy-of-Subcutaneous-VK2735-in-Adult-Participants-with-Obesity-or-Overweight-With-Weight-Related-Comorbidity.pdf)
182. [Xu et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6324399/)
183. [Zheng and Chen (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4679914/)
184. [Zvenyach and Pickering (2023)](https://pubmed.ncbi.nlm.nih.gov/37651080/)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
